November 1, 2018 / 7:52 AM / in 14 days

BRIEF-Karolinska Development: Study With Tafoxiparin Did Not Achieve Primary Endpoint

Nov 1 (Reuters) - Karolinska Development:

* SAID ON WEDNESDAY PORTFOLIO CO DILAFOR PRESENTS TOP LINE RESULTS FROM A PHASE 2B STUDY WITH TAFOXIPARIN

* STUDY DID NOT ACHIEVE ITS PRIMARY ENDPOINT OF REDUCING THE TIME TO VAGINAL DELIVERY THROUGH TREATMENT WITH TAFOXIPARIN

* KAROLINSKA DEVELOPMENT WILL REVALUE THE PORTFOLIO CO’S BOOK VALUE, WHICH IS EXPECTED TO NEGATIVELY IMPACT THE RESULT BY SEK 40 MILLION FOR Q4

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below